

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 9

Complete if Known

Application Number	10/071,829
Filing Date	February 7, 2002
First Named Inventor	Mark Douglas Howell et al.
Examiner Name	ANN Y LAM
Attorney Docket Number	034041-005

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
JC	4,116,589		Rishton	09-26-1978
	4,189,470		Rose	02-19-1980
	4,191,182		Popovich et al.	03-04-1980
	4,350,156		Malchesky et al.	09-21-1982
	4,375,414		Strahilevitz	03-01-1983
	4,486,282		Bier	12-04-1984
	4,581,010		Skurkovich et al.	04-08-1986
	4,605,394		Skurkovich	08-12-1986
	4,614,513		Bensinger	09-30-1986
	4,620,977		Strahilevitz	11-04-1986
	4,633,417		Wilburn et al.	12-30-1986
	4,634,417		Korec	01-06-1987
	4,664,913		Mielke et al.	05-12-1987
	4,801,449		Balint, Jr. et al.	01-31-1989
	4,813,924		Strahilevitz	03-21-1989
	4,824,432		Skurkovich et al.	04-25-1989
	4,834,973		Strahilevitz	05-30-1989
	4,865,841		Balint, Jr. et al.	09-12-1989
	4,963,265		Okarma et al.	10-16-1990
	5,037,645		Strahilevitz	08-06-1991
	5,037,649		Balint, Jr. et al.	08-06-1991
	5,078,673	A	Abrams	01-07-1992
	5,135,919	A	Folkman et al.	08-04-1992
	5,147,638	A	Esmon et al.	09-15-1992
	5,290,807	A	Folkman et al.	03-01-1994
	5,356,374	A	Hogan et al.	10-18-1994
	5,523,096	A	Okarma et al.	06-04-1996
	5,605,690	A	Jacobs et al.	02-25-1997
	5,629,327	A	D'Amato	05-13-1997
	5,639,725	A	O'Reilly et al.	06-17-1997
	5,643,732	A	Strahilevitz	07-01-1997
	5,679,260	A	Boos et al.	10-21-1997
	5,698,586	A	Kishimoto et al.	12-16-1997
	5,705,615	A	Lim et al.	01-06-1998
	5,712,291	A	D'Amato	01-27-1998
	5,713,491	A	Hughes et al.	02-03-1998
	5,716,981	A	Hunter et al.	02-10-1998
	5,730,713	A	Okarma et al.	03-24-1998
	5,733,876	A	O'Reilly et al.	03-31-1998
	5,753,227	A	Strahilevitz	05-19-1998
5,840,588	A	Strahilevitz	11-24-1998	
5,861,483	A	Wolpe	01-19-1999	
5,869,047	A	Blake	02-09-1999	
5,888,511	A	Skurkovich et al.	03-30-1999	
5,910,252	A	Truitt et al.	06-08-1999	
5,919,898	A	Nakatani et al.	07-06-1999	
5,980,887	A	Isner et al.	11-09-1999	

Examiner
SignatureDate
Considered

4/18/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 9

Complete if Known

Application Number 10/071,829
 Filing Date February 7, 2002
 First Named Inventor Mark Douglas Howell et al.
 Examiner Name ANN Y LAM
 Attorney Docket Number 034041-005

U.S. PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Name of Patentee or Applicant of Cited Document	Issue/Publication Date (MM-DD-YYYY)
	6,039,946	A	Strahilevitz	03-21-2000
	6,197,289	B1	Wirt et al.	03-06-2001
	6,245,038	B1	Borberg et al.	06-12-2001
	6,264,623	B1	Strahilevitz	07-24-2001
	6,287,516	B1	Matson et al.	09-11-2001
	6,428,790	B1	Boyd	08-06-2002
	6,432,405	B1	Weinberg et al.	08-13-2002
	6,528,057	B1	Ambrus et al.	03-04-2003
	6,561,997	B1	Weitzel et al.	05-13-2003
	6,569,112	B2	Strahilevitz	05-27-2003
	6,602,502	B1	Strahilevitz	08-05-2003
	6,602,993	B2	Wallach et al.	08-05-2003
	6,607,501	B2	Gorsuch	08-19-2003
	6,607,723	B1	Good et al.	08-19-2003
	6,620,382	B1	Lentz	09-16-2003
	6,627,151	B1	Borberg et al.	09-30-2003
	6,630,315	B1	Miwa et al.	10-07-2003
	6,676,622	B2	Strahilevitz	01-13-2004
	6,685,664	B2	Levin et al.	02-03-2004
	RE31688	E	Popovich et al.	09-25-1984
	RE36755	E	Smith et al.	06-27-2000
	2001/0010818	A1	Engle et al.	08-02-2001
	2001/0039392	A1	Strahilevitz	11-08-2001
	2002/0019603	A1	Strahilevitz	02-14-2002
	2002/0058031	A1	Tung et al.	05-16-2002
	2002/0086276	A1	Srivastava	07-04-2002
	2002/0107469	A1	Bolan et al.	08-08-2002
	2002/0111577	A1	Sirimanne et al.	08-15-2002
	2002/0159995	A1	Brady et al.	10-31-2002
	2002/0183677	A1	Chang et al.	12-05-2002
	2002/0187069	A1	Levin et al.	12-12-2002
	2002/0197249	A1	Brady et al.	12-26-2002
	2002/0197250	A1	Brady et al.	12-26-2002
	2002/0197251	A1	Brady et al.	12-26-2002
	2003/0073822	A1	Lofling et al.	04-17-2003
	2003/0118584	A1	Glenn et al.	06-26-2003
	2003/0125657	A1	Koll et al.	07-03-2003
	2003/0127390	A1	Davis, Jr.	07-10-2003
	2003/0133929	A1	Cham	07-17-2003
	2003/0138349	A1	Robinson et al.	07-24-2003
	2003/0148404	A1	Michaelson	08-07-2003
	2003/0163077	A1	Kim et al.	08-28-2003
	2003/0195452	A1	Hunley et al.	10-16-2003
	2003/0215443	A1	Coffey et al.	11-20-2003
	2004/0044301	A1	Levin et al.	03-04-2004
	2004/0054315	A1	Levin et al.	03-18-2004

Examiner Signature

Date Considered

4/13/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

 Sheet 3 of 9

Complete if Known

Application Number	10/071,829
Filing Date	February 7, 2002
First Named Inventor	Mark Douglas Howell et al.
Examiner Name	ANN Y LAM
Attorney Docket Number	034041-005

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Kind Code (if known)	Country	Date of Publication (MM-DD-YYYY)	STATUS						
					Translation	Partial Translation	Eng. Lang. Summary	Search Report	IPER	Abstract	Cited in Spec
<i>CE</i>	3302384	A	Germany	01-25-1983		X					
<i>CE</i>	0076665	B1	Europe	01-14-1987							
<i>CE</i>	2136314	A	UK	09-19-1984							
<i>CE</i>	56092824		Japan	07-27-1981						X	
<i>CE</i>	WO 79/01121	A1	PCT	12-27-1979							

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>CE</i>	ABBRUZZESE, J.L. ET AL., "A Phase II Trial of Recombinant Human Interferon-Gamma and Recombinant Tumor Necrosis Factor in Patients with Advanced Gastrointestinal Malignancies: Results of a Trial Terminated by Excessive Toxicity", Journal of Biological Response Modifiers, (1990), pp. 522-527, Vol. 9, Raven Press, Ltd., New York
	ADOLF AND APFLER, "A monoclonal antibody-based enzyme immunoassay for quantitation of human tumor necrosis factor binding protein I, a soluble fragment of the 60 kDa TNF receptor, in biological fluids," J. Immunol. Meth., (1991), pp. 127-136, Vol. 143
	AJANI, J.A. ET AL., "Phase I and II Studies of the Combination of Recombinant Human Interferon-γ and 5-Fluorouracil in Patients with Advanced Colorectal Carcinoma", Journal of Biological Response Modifiers, (1989), pp. 140-146, Vol. 8, Raven Press, Ltd., New York
	ALBERTINI, M.R. ET AL., "Limiting Dilution Analysis of Lymphokine-Activated Killer Cell Precursor Frequencies in Peripheral Blood Lymphocytes of Cancer Patients Receiving Interleukin-2 Therapy," Journal of Biological Response Modifiers, (1990), pp. 456-462, Vol. 9, Raven Press, Ltd., New York
	AREND, WILLIAM P., "Inhibiting the Effects of Cytokines in Human Diseases," Adv. Int. Med., (1995), pp. 365-394, Vol. 40
	AVNER, B.P. ET AL., "Therapeutic Murine Monoclonal Antibodies Developed for Individual Cancer Patients," Journal of Biological Response Modifiers, (1989), pp. 25-36, Vol. 8, Raven Press, Ltd., New York
	BALCEWICZ-SABLINSKA ET AL., "Pathogenic <i>Mycobacterium tuberculosis</i> Evades Apoptosis of Host Macrophages by Release of TNF-R2, Resulting in Inactivation of TNF-α," J. Immunol., (1998), pp. 2636-2641, Vol. 161
	BALIKO ET AL., "Th2 biased immune response in cases with active <i>Mycobacterium tuberculosis</i> infection and tuberculin anergy," FEMS Immunol. Med. Micro., (1998), pp. 199-204, Vol. 22
	BERMUDEZ AND CHAMPSI, "Infection with <i>Mycobacterium avium</i> Induces Production of Interleukin-10 (IL-10), and Administration of Anti-IL-10 Antibody Is Associated with Enhanced Resistance to Infection in Mice," Infect. Immun., (1993), pp. 3093-3097, Vol. 61
	BEUTLER AND CERAMI, "The Biology of Cachectin/TNF - A Primary Mediator of the Host Response," Ann. Rev. Immunol., (1989), pp. 625-655, Vol. 7
	BLAUER ET AL., "Modulation of the Antilisterial Activity of Human Blood-Derived Macrophages by Activating and Deactivating Cytokines," J. Interferon Cytokine Res., (1995), pp. 105-114, Vol. 15
	BOMAN, B.M., ET AL., "Phase I Study of Recombinant Gamma-Interferon (rIFN-γ)", Journal of Biological Response Modifiers, (1988), pp. 438-446, Vol. 7, Raven Press, Ltd., New York
<i>CE</i>	BRUNTSCH, U. ET AL., "Phase II Study of Recombinant Human Interferon-γ in Metastatic Renal Cell Carcinoma," Journal of Biological Response Modifiers, (1990), pp. 335-338, Vol. 9, Raven Press, Ltd., New York
Examiner Signature	Date Considered
<i>CE</i>	4/13/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 9

Complete if Known

Application Number	10/071,829
Filing Date	February 7, 2002
First Named Inventor	Mark Douglas Howell et al.
Examiner Name	ANN Y LAM
Attorney Docket Number	034041-005

NON-PATENT LITERATURE DOCUMENTSExaminer
Initials

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

York

BUKOWSKI, R.M. ET AL., "Phase I Trial of Continuous Infusion Recombinant Interleukin-2 and Intermittent Recombinant Interferon- α_{2a} : Clinical Effects", Journal of Biological Response Modifiers, (1990), pp. 538-545, Vol. 9, Raven Press, Ltd., New York

CAULFIELD, M.J. ET AL., "Phase Ia-Ib Trial of an Anti-GD3 Monoclonal Antibody in Combination with Interferon- α in Patients with Malignant Melanoma," Journal of Biological Response Modifiers, (1990), pp. 319-328, Vol. 9, Raven Press, Ltd., New York

CHAMBRIER, C. ET AL., "Hormonal and Metabolic Effects of Chronic Interleukin-2 Infusion in Cancer Patients," Journal of Biological Response Modifiers, (1990), pp. 251-255, Vol. 9, Raven Press, Ltd., New York

CHEN, ET AL., "Soluble TNF- α Receptors Are Constitutively Shed and Downregulate Adhesion Molecule Expression in Malignant Gliomas", Journal of Neuropathology and Experimental Neurology, May 1997, pp. 541-550, Vol. 56, No. 5

CHOUAIB ET AL., "More insights into the complex physiology of TNF," Immunol. Today, (1991), pp. 141-145, Vol. 12, No. 5

COCLET-NININ ET AL., "Interferon-beta not only inhibits interleukin-1 β and tumor necrosis factor- α but stimulates interleukin-1 receptor antagonist production in human peripheral blood mononuclear cells," Eur. Cytokine Network, (Dec. 1997), pp. 345-349, Vol. 8, No. 4

COLMAN, ET AL., "Hemostasis and Thrombosis: Basic Principles and Clinical Practice", (2nd Ed.), 1987, p. 63, J.B. Lippincott, Philadelphia, PA

COX, E.B., ET AL., "Phase II Study of Human Lymphoblastoid Interferon in Patients with Multiple Myeloma", Journal of Biological Response Modifiers, (1988), pp. 318-325, Vol. 7, Raven Press, Ltd., New York

CREAVEN, P.J. ET AL., "Initial Clinical Trial of the Macrophage Activator Muramyl Tripeptide-Phosphatidylethanolamine Encapsulated in Liposomes in Patients with Advanced Cancer", Journal of Biological Response Modifiers, (1990), pp. 492-498, Vol. 9, Raven Press, Ltd., New York

CROGHAN, M.K., ET AL., "A Phase I Trial of Recombinant Interferon- α and α -Difluoromethylornithine in Metastatic Melanoma", Journal of Biological Response Modifiers, (1988), pp. 409-415, Vol. 7, Raven Press, Ltd., New York

D'ANDREA ET AL., "Interleukin 10 (IL-10) Inhibits Human Lymphocyte Interferon γ -Production by Suppressing Natural Killer Cell Stimulatory Factor/IL-12 Synthesis in Accessory Cells," J. Exp. Med., (Sept. 1993), pp. 1041-1048, Vol. 178, The Rockefeller Univ. Press

DIMERY, I.W. ET AL., "Recombinant Interferon- γ in the Treatment of Recurrent Nasopharyngeal Carcinoma", Journal of Biological Response Modifiers, (1989), pp. 221-226, Vol. 8, Raven Press, Ltd., New York

DINARELLO, C.A., "Induction of Interleukin-1 and Interleukin-1 Receptor Antagonist," Sem. In Oncol., June, 1997, pp. 81-93, Vol. 24 (No. 3, Suppl. 9)

DUPERE, S. ET AL., "Patterns of Cytokines Released by Peripheral Blood Leukocytes of Normal Donors and Cancer Patients During Interleukin-2 Activation In Vitro," Journal of Biological Response Modifiers, (1990), pp. 140-148, Vol. 9, Raven Press, Ltd., New York

ELSASSER-BEILE, U., ET AL., "Increased plasma concentrations for type I and II tumor necrosis factor receptors and IL-2 receptors in cancer patients", Tumor Biology, (1994), pp. 17-24, Vol. 15

ENGELHARDT, R. ET AL., "Biological Response to Intravenously Administered Endotoxin in Patients with Advanced Cancer," Journal of Biological Response Modifiers, (1990), pp. 480-491, Vol. 9, Raven Press, Ltd., New York

ENGELMANN ET AL., "Two Tumor Necrosis Factor-binding Proteins Purified from Human Urine," J. Biol. Chem., Jan. 25, 1990, pp. 1531-1536, Vol. 265, No. 3

Examiner
SignatureDate
Considered

4/13/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 9**Complete if Known**

Application Number	10/071,829
Filing Date	February 7, 2002
First Named Inventor	Mark Douglas Howell et al.
Examiner Name	ANN Y LAM
Attorney Docket Number	034041-005

NON-PATENT LITERATURE DOCUMENTSExamining
Initials

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

- ERIKS AND EMERSON, "Temporal Effect of Tumor Necrosis Factor Alpha on Murine Macrophages Infected with *Mycobacterium avium*," Infect. Immun., (1997), pp. 2100-2106, Vol. 65, No. 6
- ETGES AND MÜLLER, "Progressive disease or protective immunity to *Leishmania major* infection: the result of a network of stimulatory and inhibitory interactions," J. Mol. Med., (1998), pp. 372-390, Vol. 76
- FAREED, G.C., ET AL., "Novel Antigenic Markers of Human Tumor Regression", Journal of Biological Response Modifiers, (1988), pp. 11-23, Vol. 7, Raven Press, Ltd., New York
- FAVROT, M.C. ET AL., "Functional and Immunophenotypic Modifications Induced by Interleukin-2 Did Not Predict Response to Therapy in Patients with Renal Cell Carcinoma," Journal of Biological Response Modifiers, (1990), pp. 167-177, Vol. 9, Raven Press, Ltd., New York
- FERNANDES AND BALDWIN, "Interleukin-10 Downregulates Protective Immunity to *Brucella abortus*," Infect. Immun., (March 1995), pp. 1130-1133, Vol. 63
- FOON, K. ET AL., "A Prospective Randomized Trial of $\alpha_2\beta_2$ -Interferon/ γ -Interferon or the Combination in Advanced Metastatic Renal Cell Carcinoma", Journal of Biological Response Modifiers, (1988), pp. 540-545, Vol. 7, Raven Press, Ltd., New York
- FROST, H. ET AL., "Interleukin-6 Induction by a Muramyltripeptide Derivative in Cancer Patients," Journal of Biological Response Modifiers, (1990), pp. 160-166, Vol. 9, Raven Press, Ltd., New York
- GADDUCCI ET AL., "Serum Levels of Soluble Receptors for Tumor Necrosis Factor (p55 and p75 sTNFr) in Endometrial Cancer," Anticancer Res., (1996), pp. 3125-3128, Vol. 16
- GILL, P.S. ET AL., "Interferon-Alpha Maintenance Therapy After Cytotoxic Chemotherapy for Treatment of Acquired Immunodeficiency Syndrome-Related Kaposi's Sarcoma", Journal of Biological Response Modifiers, (1990), pp. 512-516, Vol. 9, Raven Press, Ltd., New York
- GUSTAVSON, L.E. ET AL., "Pharmacokinetics of Teceleukin (Recombinant Human Interleukin-2) After Intravenous or Subcutaneous Administration to Patients with Cancer", Journal of Biological Response Modifiers, (1989), pp. 440-449, Vol. 8, Raven Press, Ltd., New York
- HANDZEL, Z.T. ET AL., "Immunomodulation of T Cell Deficiency in Humans by Thymic Humoral Factor: From Crude Extract to Synthetic Thymic Humoral Factor- γ_2 ," Journal of Biological Response Modifiers, (1990), pp. 269-278, Vol. 9, Raven Press, Ltd., New York
- HANK, J.A. ET AL., "Depressed In Vitro T Cell Responses Concomitant with Augmented Interleukin-2 Responses by Lymphocytes from Cancer Patients Following In Vivo Treatment with Interleukin-2", Journal of Biological Response Modifiers, (1990), pp. 5-14, Vol. 9, Raven Press, Ltd., New York
- HERCEND, T. ET AL., "Immunotherapy with Lymphokine-Activated Natural Killer Cells and Recombinant Interleukin-2: A Feasibility Trial in Metastatic Renal Cell Carcinoma", Journal of Biological Response Modifiers, (1990), pp. 546-555, Vol. 9, Raven Press, Ltd., New York
- HERRMANN, F. ET AL., "Stimulation of Granulopoiesis in Patients with Malignancy by Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor: Assessment of Two Routes of Administration," Journal of Biological Response Modifiers, (1990), pp. 475-479, Vol. 9, Raven Press, Ltd., New York
- HERTLER, ANDREW A. ET AL., "A Phase I Study of T101-Ricin A Chain Immunotoxin in Refractory Chronic Lymphocytic Leukemia", Journal of Biological Response Modifiers, (1988), pp. 97-113, Vol. 7, Raven Press, Ltd., New York
- HIMMLER ET AL., "Molecular Cloning and Expression of Human and Rat Tumor Necrosis Factor Receptor Chain (p60) and Its Soluble Derivative, Tumor Necrosis Factor-Binding Protein," DNA and Cell Biol., (1990), pp. 705-715, Vol. 9, No. 10
- JABLONSKA AND PIETRUSKA, "Release of Soluble Tumor Necrosis Factor Receptors from Polymorphonuclear Cells of Breast Cancer Patients," Arch. Immunol. Ther. Exp., (5-6 1997), pp. 449-453, Vol. 45
- JACOBS, S.J. ET AL., "Minimal Antigenicity of Intron A in Human Recipients Demonstrated by Three Analytical Methods", Journal of Biological Response Modifiers, (1988), pp. 447-456, Vol. 7, Raven Press, Ltd., New York

Examiner
SignatureDate
Considered

4/13/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 9

Complete if Known

Application Number	10/071,829
Filing Date	February 7, 2002
First Named Inventor	Mark Douglas Howell et al.
Examiner Name	ANN Y LAM
Attorney Docket Number	034041-005

NON-PATENT LITERATURE DOCUMENTSExaminer
Initials

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

JAKOBSEN ET AL., "Decreased Antitoxic Activities among Children with Clinical Episodes of Malaria," Infect. Immun., (April 1998), pp. 1654-1659, Vol. 66, No. 4

JAKSCHIES, D. ET AL., "Emergence and Decay of the Human Mx Homolog in Cancer Patients During and After Interferon- α Therapy," Journal of Biological Response Modifiers, (1990), pp. 305-312, Vol. 9, Raven Press, Ltd., New York

KALMANTI ET AL., "Serum levels of tumor necrosis factor and soluble interleukin 2 receptor as markers of disease activity and prognosis in childhood leukemia and lymphoma," Int. J. Hematol., (1993), pp. 147-152, Vol. 57, Elsevier Scientific Publishers Ireland Ltd.

KAUFMANN ET AL., "T cells and cytokines in intracellular bacterial infections: experiences with *Mycobacterium bovis* BCG," Ciba Fdn. Symp., (1995), pp. 123-132, Vol. 195KELLOKUMPU-LEHTINEN, P. ET AL., "Recombinant Interferon- α 2a and Vinblastine in Advanced Renal Cell Cancer: A Clinical Phase I-II Study, Journal of Biological Response Modifiers, (1990), pp. 439-444, Vol. 9, Raven Press, Ltd., New York

KHAZAEI, M.B. ET AL., "Initial Evaluation of a Human Immunoglobulin M Monoclonal Antibody (HA-1A) in Humans, Journal of Biological Response Modifiers, (1990), pp. 178-184, Vol. 9, Raven Press, Ltd., New York

KOLITZ, J.E. ET AL., "Phase I Trial of Recombinant Interleukin-2 and Cyclophosphamide: Augmentation of Cellular Immunity and T-Cell Mitogenic Response with Long-Term Administration of rIL-2", Journal of Biological Response Modifiers, (1988), pp. 457-472, Vol. 7, Raven Press, Ltd., New York

KRIGEL, R.L. ET AL., "Treatment of Epidemic Kaposi's Sarcoma with a Combination of Interferon-Alpha 2_b and Etoposide", Journal of Biological Response Modifiers, (1988), pp. 359-364, Vol. 7, Raven Press, Ltd., New York

LANTZ ET AL., "Infusion of Tumor Necrosis Factor (TNF) Causes an Increase in Circulating TNF-Binding Protein in Humans," Cytokine, (Nov. 1990), pp. 402-406, Vol. 2, No.6

LASZLO, J. ET AL., "Phase I Studies of Recombinant Interferon- γ ", Journal of Biological Response Modifiers, (1990), pp. 185-193, Vol. 9, Raven Press, Ltd., New YorkLAUCELLA ET AL., "Papel de las citoquinas en la resistencia y patología durante la infección con *Trypanosoma cruzi*," Revista Argentina de Microbiología, (1996), pp. 99-109, Vol. 28

LENTZ, M. R., ET AL., "Apheresis of Low Molecular Weight Protein Fraction and the Onset of Labor", Journal of Clinical Apheresis, (1990), pp. 62-67, Vol. 5

LENTZ, M. R., "The phylogeny of oncology", Mol. Biother., Sept. 1990, pp. 137-144, Vol. 2

LETTERIO AND ROBERTS, "Regulation of Immune Responses by TGF- β ," Ann Rev. Immunol., (1998), pp. 137-161, Vol. 16

LITTON, G.J. ET AL., "Biological and Clinical Effects of the Oral Immunomodulator 3,6-Bis(2-piperidinoethoxy)acridine Trihydrochloride in Patients with Malignancy", Journal of Biological Response Modifiers, (1990), pp. 61-70, Vol. 9, Raven Press, Ltd., New York

LUCEY ET AL., "Type 1 and Type 2 Cytokine Dysregulation in Human Infectious, Neoplastic, and Inflammatory Diseases," Clin. Micro. Rev., (Oct. 1996), pp. 532-562, Vol. 9, No. 4

MAAS ET AL., "Interleukin-2 in cancer treatment: disappointing or (still) promising? A review," Cancer Immunol. Immunother., (1993), pp. 141-148, Vol. 36

MACA, RICHARD D., "Inhibition of the Growth of Lewis Lung Carcinoma by Indomethacin in Conventional, Nude, and Beige Mice," Journal of Biological Response Modifiers, (1990), pp. 568-580, Vol.9, Raven Press, Ltd., New York

MARSHALL, M.E. ET AL., "Effects of Coumarin (1,2-Benzopyrone) and Cimetidine on Peripheral Blood Lymphocytes, Natural Killer Cells, and Monocytes in Patients with Advanced Malignancies," Journal of Biological Response Modifiers, (1989), pp. 62-69, Vol. 8, Raven Press, Ltd., New York

MARSHALL, M.E. ET AL., "Treatment of Renal Cell Carcinoma with Daily Low-Dose Alpha-Interferon," Journal of Biological Response Modifiers, (1989), pp. 453-461, Vol. 8, Raven Press, Ltd., New York

Examiner
SignatureDate
Considered

4/13/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 7 of 9

Complete if Known

Application Number	10/071,829
Filing Date	February 7, 2002
First Named Inventor	Mark Douglas Howell et al.
Examiner Name	ANN Y LAM
Attorney Docket Number	034041-005

NON-PATENT LITERATURE DOCUMENTSExaminer
Initials

Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.

MATSCHINER, ET AL., "Heterogeneity of Protein C and Factor X From Human Plasma," Current Advances in Vitamin K Research, 1988, pp. 135-140, John W. Suttie, Ed. (Elsevier Science Publishing Co., Inc.)

MCLEOD, BRUCE C. ET AL. Eds, "Apheresis: Principles and Practice," (1997), AABB Press, Bethesda, MD

MILES ET AL., "Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2," Brit. J. Cancer, 1992, pp. 1195-1199, Vol. 66

MITTELMAN, A. ET AL., "Treatment of Patients with Advanced Cancer Using Multiple Long-Term Cultured Lymphokine-Activated Killer (LAK) Cell Infusions and Recombinant Human Interleukin-2", Journal of Biological Response Modifiers, 1989, pp. 468-478, Vol. 8, Raven Press, Ltd., New York

MUSIANI, P. ET AL., "Effect of Low Doses of Interleukin-2 Injected Perilymphatically and Peritumorally in Patients with Advanced Primary Head and Neck Squamous Cell Carcinoma", Journal of Biological Response Modifiers, 1989, pp. 571-578, Vol. 8, Raven Press, Ltd., New York

NEIDHART, J.A., "Phase I Study of Recombinant Methionyl Human Consensus Interferon (r-methHuIFN-Con₁), Journal of Biological Response Modifiers, 1988, pp. 240-248, Vol. 7, Raven Press, Ltd., New York

ORATZ, R. ET AL., "Induction of Tumor-Infiltrating Lymphocytes in Human Malignant Melanoma Metastases by Immunization to Melanoma Antigen Vaccine," Journal of Biological Response Modifiers, 1989, pp. 355-358, Vol. 8, Raven Press, Ltd., New York

ORATZ, R. ET AL., "Antimelanoma Monoclonal Antibody-Ricin A Chain Immunoconjugate (XMMME-001-RTA) Plus Cyclophosphamide in the Treatment of Metastatic Malignant Melanoma: Results of a Phase II Trial", Journal of Biological Response Modifiers, 1990, pp. 345-354, Vol. 9, Raven Press, Ltd., New York

PAIS, R.C. ET AL., "Pharmacokinetics of Recombinant Interleukin-2 in Children with Malignancies: A Pediatric Oncology Group Study", Journal of Biological Response Modifiers, 1990, pp. 517-521, Vol. 9, Raven Press, Ltd., New York

PAOLOZZI, F. ET AL., "Phase I Trial of Recombinant Interleukin-2 and Recombinant β -Interferon in Refractory Neoplastic Diseases, Journal of Biological Response Modifiers, 1989, pp. 122-139 Vol.8, Raven Press, Ltd., New YorkPEREZ, R. ET AL., "A Phase I Trial of Recombinant Human Gamma Interferon (IFN- γ_{4A}) in Patients with Advanced Malignancy", Journal of Biological Response Modifiers, 1988, pp. 309-317, Vol. 7, Raven Press, Ltd., New York

QUESADA, J.R. ET AL., "Recombinant Interferon Alpha and Gamma in Combination as Treatment for Tetastatic Renal Cell Carcinoma", Journal of Biological Response Modifiers, 1988, pp. 234-239, Vol. 7, Raven Press, Ltd., New York

RABINOWITZ, A.P. ET AL., "Hemolytic Anemia in a Cancer Patient Treated with Recombinant Interferon- γ ", Journal of Biological Response Modifiers, 1990, pp. 256-259, Vol. 9, Raven Press, Ltd., New York

REIMANN, J ET AL., "Suppression of the Immune Response by Micro-Organisms," Scand. J. Immunol., 1990, pp. 543-546, Vol. 31

RIFFKIN ET AL., "Defence against the immune barrage; Helminth survival strategies," Immunol. Cell Biol., 1996, pp. 564-574, Vol. 74

ROMANI ET AL., "T Helper Cell Dichotomy to *Candida albicans*: Implications for Pathology, Therapy, and Vaccine Design," Immunol. Res., 1995, pp. 148-162, Vol. 14

ROSENTHAL, N.S., ET AL., "The In Vitro Function of Lymphocytes from 25 Cancer Patients Receiving Four to Seven Consecutive Days of Recombinant IL-2", Journal of Biological Response Modifiers, 1988, pp. 123-139, Vol. 7, Raven Press, Ltd., New York

RYBAK, M.E. ET AL., "Interferon Therapy of Relapsed and Refractory Hodgkin's Disease: Cancer and Leukemia Group B Study 8652", Journal of Biological Response Modifiers, 1990, pp. 1-4, Vol. 9, Raven Press, Ltd., New York

SARNA, G.P. ET AL., "Systemic Administration of Recombinant Methionyl Human Interleukin-2 (Ala 125) to Cancer Patients: Clinical Results," Journal of Biological Response Modifiers, 1989, pp. 16-24, Vol. 8, Raven Press, Ltd., New York

Examiner
SignatureDate
Considered

4/12/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 9

Complete if Known

Application Number	10/071,829
Filing Date	February 7, 2002
First Named Inventor	Mark Douglas Howell et al.
Examiner Name	ANN Y LAM
Attorney Docket Number	034041-005

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
	SARNA, G. ET AL., "A Pilot Study of Intralymphatic Interleukin-2. II. Clinical and Biological Effects," Journal of Biological Response Modifiers, (1990), pp. 81-86, Vol. 9, Raven Press, Ltd., New York
	SARTHOE ET AL., "Prognostic Value of Anti-Plasmodium falciparum-Specific Immunoglobulin G3, Cytokines, and Their Soluble Receptors in West African Patients with Severe Malaria," Infect. Immun. 1997, pp. 3271-3276, Vol. 65, No. 8
	SATO, M. ET AL., "Induction of Bone Formation in an Adenoid Cystic Carcinoma of the Maxillary Sinus by Adoptive Immunotherapy Involving Intra-Arterial Injection of Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 in Combination with Radiotherapy," Journal of Biological Response Modifiers, 1990, pp. 329-334, Vol. 9, Raven Press, Ltd., New York
	SCHAADT, M. ET AL., "Phase II Study of Recombinant Human Tumor Necrosis Factor in Colorectal Carcinoma", Journal of Biological Response Modifiers, 1990, pp. 247-250, Vol. 9, Raven Press, Ltd., New York
	SCHALL ET AL., "Molecular Cloning and Expression of a Receptor for Human Tumor Necrosis Factor," Cell, April 20, 1990, pp. 361-370, Vol. 61
	SCHIEITHAUER, W. ET AL., "Combined α -2C-Interferon/VMCP Polychemotherapy Versus VMCP Polychemotherapy a Induction Therapy in Multiple Myeloma: A Prospective Randomized Trial," Journal of Biological Response Modifiers, 1989, pp. 109-115, Vol. 8, Raven Press, Ltd., New York
	SCHILLER, J.H. ET AL., "A Phase I Trial of Interferon- α -2a plus Cyclophosphamide, Vincristine, Prednisone, and Doxorubicin", Journal of Biological Response Modifiers, 1989, pp. 252-261, Vol. 8, Raven Press, Ltd., New York
	SECKINGER ET AL., "Purification and Biologic Characterization of a Specific Tumor Necrosis Factor α Inhibitor," J. Biol. Chem., July 15, 1989, pp. 11966-11973, Vol. 264, No. 20
	SEIGLER, H.F. ET AL., "Melanoma Patient Antibody Responses to Melanoma Tumor-Associated Antigens Defined by Murine Monoclonal Antibodies," Journal of Biological Response Modifiers, 1989, pp. 37-52, Vol. 8, Raven Press, Ltd., New York
	SHAU, H. ET AL., "A Pilot Study of Intralymphatic Interleukin-2. I. Cytotoxic and Surface Marker Changes of Peripheral Blood Lymphocytes," Journal of Biological Response Modifiers, 1990, pp. 71-80, Vol. 9, Raven Press, Ltd., New York
	SIDHU AND BOLLON, "Tumor Necrosis Factor Activities and Cancer Therapy - A Perspective," Pharmacol. Ther., 1993, pp. 79-128, Vol. 57
	SIELING ET AL., "Immunosuppressive Roles for IL-10 and IL-4 in Human Infection," J. Immunol., June 15, 1993, pp. 5501-5510, Vol. 150, No. 12
	SPRIGGS, M.K., "One Step Ahead of the Game: Viral Immunomodulatory Molecules," Ann. Rev. Immunol., 1996, pp. 101-130, Vol. 14
	STEGE, G.G. ET AL., "Long-Term Remission in a Patient with Erythroleukemia Following Interferon- α Treatment," Journal of Biological Response Modifiers, 1989, pp. 351-354, Vol. 8, Raven Press, Ltd., New York
	STEINMETZ, T. ET AL., "Phase I Study of 24-Hour Continuous Intravenous Infusion of Recombinant Human Tumor Necrosis Factor", Journal of Biological Response Modifiers, 1988, pp. 417-423, Vol. 7, Raven Press, Ltd., New York
	SZOL, M. ET AL., "A Phase I Study of High-Dose Interleukin-2 in Combination with Interferon- α 2b," Journal of Biological Response Modifiers, 1990, pp. 529-537, Vol. 9, Raven Press, Ltd., New York
	TRIGG, M.E. ET AL., " α -Interferon Therapy for Lymphoproliferative Disorders Developing in Two Children Following Bone Marrow Transplants," Journal of Biological Response Modifiers, 1989, pp. 603-613, Vol. 8, Raven Press, Ltd., New York
	TRINCHIERI ET AL., "Cytokine Cross-Talk Between Phagocytic Cells and Lymphocytes: Relevance for Differentiation/Activation of Phagocytic Cells and Regulation of Adaptive Immunity," J. Cell. Biochem., 1993, pp. 301-308, Vol. 53

Examiner
SignatureDate
Considered

4/13/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

THIRD INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 9 of 9

Complete if Known

Application Number	10/071,829
Filing Date	February 7, 2002
First Named Inventor	Mark Douglas Howell et al.
Examiner Name	ANN Y LAM
Attorney Docket Number	034041-005

NON-PATENT LITERATURE DOCUMENTS

Examiner Initials	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
✓	TRUMP, D.L. ET AL., "Interferon- α -n1 and Continuous Infusion Vinblastine for Treatment of Advanced Renal Cell Carcinoma", Journal of Biological Response Modifiers, 1990, pp. 108-111, Vol. 9, Raven Press, Ltd., New York
✓	UMIEL, T. ET AL., "Recombinant Interleukin-2-Activated Intracavitary Lymphocytes: Phenotypic Characteristics and Effector Function", Journal of Biological Response Modifiers, 1989, pp. 409-421, Vol. 8, Raven Press, Ltd., New York
✓	VON HOFF, D.D. ET AL., "Phase II Evaluation of Recombinant γ -Interferon in Patients with Advanced Pancreatic Carcinoma: A Southwest Oncology Group Study", Journal of Biological Response Modifiers, 1990, pp. 584-587, Vol. 9, Raven Press, Ltd., New York
✓	WALSH, C. ET AL., "Phase I Study of the Combination of Alpha-2 Interferon and Cisplatin", Journal of Biological Response Modifiers, 1989, pp. 11-15, Vol. 8, Raven Press, Ltd., New York
✓	WEIL-HILLMAN, G. ET AL., "Transient Decrease in IL-2-Responsive Lymphocytes 24 Hours After Initiation of Continuous IL-2 Infusion in Cancer Patients", Journal of Biological Response Modifiers, 1988, pp. 424-437, Vol. 7, Raven Press, Ltd., New York
✓	WHITEHEAD, R.P. ET AL., "A Phase II Trial of Recombinant Tumor Necrosis Factor in Patients with Metastatic Colorectal Adenocarcinoma: A Southwest Oncology Group Study", Journal of Biological Response Modifiers, 1990, pp. 588-591, Vol. 9, Raven Press, Ltd., New York
✓	ZAMKOFF, K.W. ET AL., "A Phase I Trial of Subcutaneously Administered Recombinant Tumor Necrosis Factor to Patients with Advanced Malignancy", Journal of Biological Response Modifiers, 1989, pp. 539-552, Vol. 8, Raven Press, Ltd., New York

Examiner
SignatureDate
Considered

4/13/05

*EXAMINER: Initial reference considered, whether or not citation is in conformance with M.P.E.P. § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.